Related Experiment Videos
[Further experiences with the Imurek treatment in multiple sclerosis]
Psychiatrie, Neurologie, Und Medizinische Psychologie
|September 1, 1981
Summary
This study on multiple sclerosis (MS) patients found Imurek treatment showed best results in acute episodes. Chronic cases saw limited improvement, with most experiencing no change or deterioration, alongside notable side effects.
Area of Science:
- Neurology
- Immunology
Context:
- Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system.
- Long-term treatment outcomes and side effects of immunomodulatory therapies require ongoing investigation.
Purpose:
- To evaluate the efficacy and safety of Imurek (azathioprine) in a cohort of 82 patients with multiple sclerosis over an extended treatment period (up to 8 years).
Summary:
- The study observed varying responses to Imurek treatment in 82 MS patients.
- Patients experiencing acute MS episodes demonstrated the most favorable outcomes.
- In chronic-progressive MS, 5.1% improved, 24.4% remained stable, and 64.1% deteriorated.
- Reported side effects included gastrointestinal issues, leukopenia, edema, hair loss, goiter, elevated transaminases, and infections.
Impact:
- Findings suggest Imurek may be more beneficial in acute MS phases.
- The high rate of deterioration and significant side effects in chronic-progressive MS highlight the need for careful patient selection and monitoring.
- Recommends specific treatment criteria and intensive patient supervision for Imurek therapy in MS management.